While poly ADP-ribose polymerase (PARP) inhibitors have demonstrated promising therapeutic benefits in high-grade serous ovarian cancer (HGSOC) patients [120], there are concerns regarding the complexity of mechanisms underlying resistance to PARP inhibition. This evidence concerns the gene PARP1 and ovarian serous adenocarcinoma.